Use of CRF receptor agonists for the treatment or Prophylaxis of diseases, for example Neurodegenerative diseases
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 15, 2008
app pub date -
Aug 1, 2006
filing date -
Mar 31, 2000
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
CRF receptor agonists, especially CRF receptor-1 agonists such as CRF, urocortin, sauvagine or urotensin 1, can be used for the prevention or inhibition of neuronal cell death in a mammal suffering from or susceptible to chronic neurodegenerative disease (e.g. Alzheimer's disease, Parkinson's disease or Huntington's disease), traumatic (mechanical) neuronal injury, epilepsy-associated neuronal loss, paralysis, or spinal chord injury. CRF receptor-1 agonists can also be administered to aid the prevention or inhibition of neuronal cell death in a mammal suffering from or suceptible to cerebral ischaemia (stroke). Also, where neuronal cell death is potentiated by inhibition or suppression of the PI 3-kinase signalling pathway, a treatment comprises administering to the mammal an effective amount of a CRF receptor agonist.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully